September 2016, Vol. 5, No. 7

← Back to Issue

Scalp Cooling Now More Commonly Used in the United States

MASCC/ISOO

hope-rugo98pxBecause of the recent approval by the FDA of the DigniCap system1 and growing evidence that scalp cooling is an effective treatment for preventing chemotherapy-induced alopecia, the practice is steadily becoming more widespread in the United States. And Hope S. Rugo, MD, is leading the charge on educating patients and providers on cooling options.

According to Dr Rugo, Director of the Breast Oncology Clinical Trials Program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, scalp cooling has historically not been available in the United States, despite substantial patient interest.

“Even though huge data sets were available, there was concern that this wasn’t an effective method of preventing hair loss,” she said at the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.2 “There was also concern over the potential risk of increased scalp metastases and thermal injury from scalp cooling, but the data have fairly definitively shown that there is no increased risk.”

The Penguin Cold Cap versus Freestanding Systems

Penguin Cold Caps are patented, insulated gel caps that must be cooled in a freezer or on dry ice to −35 degrees Celsius before use. Since patients can rent the caps themselves and use their own cooler or special freezer—ie, medical centers do not have to provide them or play a role in their use—these caps have been the most frequently used scalp cooling device in the United States until very recently.

However, since helpers must be present for the duration of treatment to change the caps every 20 to 30 minutes, and the number of cold caps required is dependent on the type and duration of chemotherapy administration, following the recommendations exactly can be costly.

DigniCap, a self-contained system that circulates coolant through a tight-fitting silicone cap with temperature sensors connected to the cooling and control unit, was granted FDA approval in December 2015 based on the results of a pivotal trial led by Dr Rugo.

“Our challenge was convincing the FDA of the importance of preventing hair loss, so we pointed out the fact that many thousands of women have used the Penguin Cold Cap,” she said. “They were also worried [the study] wasn’t feasible, but we were able to demonstrate excellent feasibility and efficacy.”

The researchers found the system to be highly effective in reducing chemotherapy-induced alopecia, with clinically meaningful benefit. In the study, 66.3% of patients with breast cancer receiving neoadjuvant chemotherapy who used the DigniCap lost less than half of their hair, compared with the control group (patients who opted out of scalp cooling entirely), all of whom experienced significant hair loss; the treatment was also found to be safe and well tolerated. Mean follow-up is now close to 2.5 years with plans to continue, and no scalp metastases have been observed in the treatment group.

The Orbis Paxman Scalp Cooling System is similar to the DigniCap system and is currently being tested in a US randomized trial that will provide eagerly awaited safety data. “We hope this trial will lead to FDA clearance of the Paxman machine as well, but what’s important about this trial is it will provide some crucial safety data that will be unequaled in a prospective trial,” said Dr Rugo.

The Future of Scalp Cooling

In the short term, patients sometimes complain about a cold sensation, or “brain freeze,” or headache from scalp cooling. Dr Rugo said she has seen occasional dermatitis and skin thermal injury, but only with the use of Penguin Cold Caps, which require strict temperature regulation. The main long-term concern has been the increased risk of scalp metastases, but she reiterated that “numerous studies in scalp-cooled patients suggest no difference in risk.”

According to Dr Rugo, patients and oncology providers should be better informed about scalp cooling options. Improvements in scalp cooling technology are crucial, as are the coordination of access and post-cooling time issues, or “chair time.”

In the United States, where out-of-pocket costs can create barriers to care, organizations like HairToStay offer financial aid to patients to offset the cost of scalp-cooling treatment for those who fall below the poverty line. Dr Rugo and her colleagues have also spent considerable time and effort to cap the cost of the DigniCap system so that patients don’t have to pay every time they use it. “We don’t want scalp cooling to only be an option for people who have money and access,” she said.

References

  1. US Food and Drug Administration. FDA allows marketing of cooling cap to reduce hair loss during chemotherapy [press release]. December 8, 2015. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476216.htm. Accessed July 21, 2016.
  2. Rugo H. Recent US trials of scalp cooling. Presented at: MASCC/ISOO Annual Meeting on Supportive Care on Cancer; June 23-25, 2016; Adelaide, Australia.
MASCC/ISOO - September 12, 2016

“Magic Mouthwash” and the Management of mTOR Inhibitor–Associated Stomatitis

Stomatitis is a dose-limiting toxicity associated with the use of mammalian target of rapamycin (mTOR) inhibitors, but new treatments can improve quality of life for patients suffering from this often debilitating condition, according to data presented at the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology [ Read More ]

Prostate Cancer - September 12, 2016

Personalized Approach to Prostate Cancer

In 2016, prostate cancer is projected to be the most common cancer among men (excluding skin cancers), occurring in 180,890 and causing death in 26,120.1 The median age at time of diagnosis of prostate cancer is 66 years, with the median age at death being 80 years.2 Simply considering both [ Read More ]